61636-32-6

Basic information

• Product Name: 4-BENZYL-MORPHOLIN-3-ONE
• Synonyms: 4-BENZYL-MORPHOLIN-3-ONE
• CAS NO: 61636-32-6
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 61636-32-6.mol

Chemical Properties

• Boiling Point: 379.3°C at 760 mmHg
• Flash Point: 183.2°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 5.92E-06mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• PKA: -0.95±0.20(Predicted)
• CAS DataBase Reference: 4-BENZYL-MORPHOLIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYL-MORPHOLIN-3-ONE(61636-32-6)
• EPA Substance Registry System: 4-BENZYL-MORPHOLIN-3-ONE(61636-32-6)

Safety Data

• Hazardous Substances Data: 61636-32-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H13NO2/c13-11-9-14-7-6-12(11)8-10-4-2-1-3-5-10/h1-5H,6-9H2

Upstream product

• 100129-49-5 N-benzyl-2-chloro-N-(2-hydroxyethyl)acetamide 
• 349097-85-4 N-benzyl-3-chloro-N-(2-hydroxyethyl)propanamide 
• 10316-00-4 4-benzyl-morpholine 
• 2564-83-2 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 104-63-2 N-Benzylethanolamine 

Downstream Products

• 40987-24-4 R,S-2-hydroxymethyl-4-benzylmorpholine 
• 1450995-69-3 (2R,3S)-4-benzyl-2-[hydroxy-(4-chlorophenyl)methyl]-morpholin-3-one 
• 668471-06-5 4-benzyl-2-(1-hydroxy-2-methyl-propyl)-morpholin-3-one 
• 1450995-70-6 (2R,3S)-4-benzyl-2-(hydroxy-p-tolylmethyl)morpholin-3-one 
• 800407-90-3 (2R,3S)-4-benzyl-2-(hydroxyphenylmethyl)morpholin-3-one 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Selective, Catalytic, and Dual C(sp3)-H Oxidation of Piperazines and Morpholines under Transition-Metal-Free Conditions

By using cheap and innocuous reagents, such as NaClO2, NaOCl, and catalytic amounts of TEMPO, a new environmentally friendly protocol for the selective and catalytic TEMPO C(sp3)-H oxidation of piperazines and morpholines to 2,3-diketopiperazines (2,3-DKP) and 3-morpholinones (3-MPs), respectively, has been developed. This novel direct access to 2,3-DKP from piperazines provides significant advantages over the traditional N-monoacylation/intramolecular C-N cyclization procedure. Additionally, by modulating the amounts of TEMPO, 2-alkoxyamino-3-morpholinone can be prepared from morpholine derivatives, which would enable further functionalization at the C2 position of the morpholine skeleton.

Transition-Metal-Free Amine Oxidation: A Chemoselective Strategy for the Late-Stage Formation of Lactams

A metal-free strategy for the formation of lactams via selective oxidation of cyclic secondary and tertiary amines is described. Molecular iodine facilitates both chemoselective and regioselective oxidation of C-H bonds directly adjacent to a cyclic amine. The mild conditions, functional group tolerance, and substrate scope are demonstrated using a suite of diverse small molecule cyclic amines, including clinically approved drug scaffolds.

ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES

The present invention relates to compounds of the formula (I) wherein R1, R2, R3, X, Y and the dashed line are defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.

TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS

Provided are methods and medicaments for treating a learning disability or a Motor Skills Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.

TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS

Provided are methods and medicaments for treating a Pervasive Developmental Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.

MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS

Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.

TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION

Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.

Novel compounds

The present invention provides compounds of Formula I wherein R1, R2, R3, and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment

MORPHOLINE DERIVATIVES

Compounds of formula (I), wherein: A is S or O; R is H; Ar is an optionally substituted phenyl group; X is an optionally substituted phenyl group, a C1-C4 alkyl, a C3-C6 cycloalkyl group or a CH2(C3-C6 cycloalkyl) group; R' is H or C1-C4 alkyl; and each R